Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase II Trial of Trastuzumab (Herceptin) Continuation in Combination With 2nd-line Chemotherapies After Progression on a 1st-line Chemotherapy Combined With Trastuzumab in Patients With HER2 Positive Metastatic Breast Cancer (Treatment Beyond Progression, TBP)

NCT00444587 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00444587
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00444587 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase II Trial of Trastuzumab (Herceptin) Continuation in Combination With 2nd-line Chemotherapies After Progression on a 1st-line Chemotherapy Combined With Trastuzumab in Patients With HER2 Positive Metastatic Breast Cancer (Treatment Beyond Progression, TBP)
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2007
Completion date
August 31, 2011
Enrollment
114 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer